132 related articles for article (PubMed ID: 16595817)
1. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
[No Abstract] [Full Text] [Related]
2. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
4. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
[TBL] [Abstract][Full Text] [Related]
5. [Drugs: piperacillin/tazobactam].
Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):132-3. PubMed ID: 7711129
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
[TBL] [Abstract][Full Text] [Related]
8. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
Lau WK; Mercer D; Itani KM; Nicolau DP; Kuti JL; Mansfield D; Dana A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3556-61. PubMed ID: 16940077
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
Jansen JP; Kumar R; Carmeli Y
Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
[TBL] [Abstract][Full Text] [Related]
14. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
[TBL] [Abstract][Full Text] [Related]
16. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
18. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
